Triple-negative breast cancer has entered a new era.

At ESMO 2025, TRO-Breast02 and ASCENT-03 delivered practice-shifting data — from rapid progressors to PD-L1–defined pathways and the growing role of TROP2-targeted ADCs.

Dr. Neil Iyengar and Dr. Erika Hamilton break down trial design differences, crossover implications, toxicity management, and how these results will shape first-line treatment decisions for TNBC.

#BreastCancer #TNBC #TripleNegativeBreastCancer #TROP2 #ADCs #TDXd #SacituzumabGovitecan #ASCENT03 #TROB02 #ESMO2025 #Oncology #CancerResearch #CHM

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

The landscape of HER2+ and HER2-low breast cancer is shifting fast — and DB-05 and DB-11 are at the center of it.

In this deep-dive from ESMO 2025, Dr. Gregory Vidal and Dr. Erika Hamilton break down what the latest T-DXd data means for real-world practice, how ILD should be monitored, and why sequencing matters more than ever.

#BreastCancer #HER2 #HER2Low #TDXd #TrastuzumabDeruxtecan #ESMO2025 #DB05 #DB11 #OncologyEducation #CancerResearch #MedicalOncology #CHM

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

At ESMO Berlin, Dr. Mark Pegram and Dr. Ana Garrido-Castro break down breakthrough data shaping the new standard for first-line metastatic triple-negative breast cancer (TNBC).

Together, they unpack results from ASCENT-03 and TROPION-Breast02, where Trop-2 antibody-drug conjugates demonstrated significant improvements in response rates, PFS, and — in one study — overall survival.

Drs. Pegram and Garrido-Castro explore:

• Why Trop-2 ADCs may replace chemotherapy in PD-L1–negative TNBC

• Key differences in trial design, patient selection, and endpoints

• Real-world decision-making based on toxicity, dosing schedules, and prophylaxis

• How HR-low disease, BRCA/PALB2 status, and CNS involvement factor into treatment strategy

A must-listen for clinicians navigating the fast-evolving landscape of metastatic TNBC and the rise of ADC-driven precision therapy.

#BreastCancer #TNBC #TripleNegativeBreastCancer #ESMO2025 #OncologyPodcast #Trop2 #ADCtherapy #CancerResearch #ClinicalOncology #BreastOncology #PrecisionOncology #CHM

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Achieving pCR has long been considered the “holy grail” in HER2+ breast cancer — but does it truly guarantee protection from recurrence, especially in the brain?

In this conversation, Drs. Jason Mouabbi, Irene Kang, and Ruemu Birhiray explore evolving perspectives on pCR, CNS relapse, and the emerging role of neratinib in protecting high-risk patients. They discuss new data, the unmet need for CNS-active strategies, and how upcoming trials like DESTINY-Breast05 and COMPASS-HER2 RD could redefine the adjuvant landscape.

Watch to understand what’s next for HER2+ disease — and how oncologists are rethinking long-term protection beyond pathologic complete response.

📺 Subscribe to Community Health Media for more expert-led oncology conversations.

🎧 Stream the full episode on Spotify, Apple Podcasts, or YouTube.

#BreastCancer #HER2Positive #Oncology #BreastCancerResearch #BreastCancerAwareness #Neratinib #Trastuzumab #CancerCare #MedicalOncology #CancerResearch #CHM #CommunityHealth #Podcast #ClinicalOncology #AdjuvantTherapy #CancerEducation

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

From testing to treatment, the conversation around PARP inhibition in breast cancer is rapidly evolving.

In this episode, Dr. Neil Iyengar and Dr. Mark Robson explore how germline testing, risk stratification, and therapy sequencing are shaping adjuvant treatment decisions for BRCA1/2-mutated breast cancer.

They discuss:

🔹 Who should be tested — and how testing criteria are expanding.

🔹 Key takeaways from OlympiA and long-term data on olaparib.

🔹 The balance between PARP inhibitors, CDK4/6 inhibitors, and IO-based regimens.

🔹 How toxicity, sequencing, and emerging biomarkers like MRD may guide the future of adjuvant therapy.

Stay ahead of the data in this forward-looking conversation on personalizing care for high-risk HER2-negative breast cancer.

📺 Subscribe to Community Health Media and stream the full conversation on YouTube, Spotify, or your favorite podcast platform.

#CommunityHealthMedia #BreastCancerResearch #AdjuvantTherapy #PARPInhibitors #Olaparib #OlympiAStudy #BRCA #OncologyPodcast #BreastOncology #CancerCare #PrecisionOncology #OncologyEducation

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Direct from ESMO 2025 in Berlin, Dr. Mark Pegram and Dr. Neil Iyengar unpack what many are calling a new standard in HER2-directed therapy.

From DESTINY-Breast 11’s practice-changing neoadjuvant results to DESTINY-Breast 05 in the adjuvant setting — and now DESTINY-Breast 09 rewriting the metastatic playbook — the data are clear: trastuzumab deruxtecan (T-DXd) is transforming treatment across disease stages.

The discussion moves beyond HER2 + disease into HER2-low and ultra-low, touching on how new definitions, ADC sequencing, and precision testing could expand eligibility to the majority of breast cancers.

🎧 Tune in for a high-impact, expert-level recap of the trials defining the next chapter of HER2 oncology.

#BreastCancer #ESMO2025 #OncologyPodcast #HER2Positive #HER2Low #TDXd #Pegram #Iyengar #TrastuzumabDeruxtecan #CancerResearch #BreastOncology #PrecisionOncology #CHM

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Watch this enlightening conversation focused on the transforming power of antibody-drug conjugates (ADCs) like T-DXd (trastuzumab deruxtecan) in HER2-positive breast cancer therapy with Dr. Anne O’Dea and Dr. VK Gadi. The doctors provide hope for T-DXd’s potential usage as a first-line treatment, which could change present guidelines away from conventional chemotherapy treatments like the Cleopatra regimen, notable for their high toxicity. Effective, focused therapy with less side effects provided by T-DXd could improve patients’ quality of life and maybe increase general survival.They also discuss the value of HER2 testing, pointing out that patients labeled as HER2-low or ultra-low could still benefit from T-DXd , therefore stressing the need of more exact diagnostic criteria. Trials like DB12 and DESTINY-Breast06 under progress allow Dr. O’Dea and Dr. Gadi optimism for improved understanding of ideal therapy sequencing, particularly for managing brain metastases—a major difficulty in HER2-positive cases.Emphasizing personalizing, strategic sequencing, and future research to generate better outcomes and, finally, the possibility for more curative medicines, their discussion shows an emerging approach to HER2 treatment.🎧 Don’t forget to like, share, and subscribe for more CHM Conversations#BreastCancer #OncologyPodcast #TDXd #HER2Low #CHMConversations #PrecisionMedicine #CancerResearch–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Join Dr. VK Gadi and Dr. Jason Mouabbi at a recent conference for their discussion around the changing function of antibody-drug conjugates (ADCs) such as T-DXd (trastuzumab deruxtecan) in treating HER2-positive breast cancer, especially in patients with central nervous system (CNS) metastases. The talk hinges on the historical use of tiny compounds like tucatinib to ensure they’re able to pass the blood-brain barrier. New research, however, challenges the conventional wisdom on treatment restrictions by showing that ADCs might also be useful in this environment.

Dr. Mouabbi offered a real-world illustration of T-DXd’s transforming power by sharing a clinical case whereby it produced amazing regression of both visceral and central nervous system disorders. Data from studies like as DESTINY-Breast04 and the forthcoming DB12 study, which concentrates on patients with untreated or stable brain metastases, could provide vital direction on T-DXd’s efficacy in CNS care. In line with the encouraging findings observed in clinical practice, this trial seeks to confirm T-DXd’s influence on brain metastases.

The discussion also touches on the need for closely monitoring patients, especially for possible side effects including interstitial lung disease (ILD), with doctors using routine CT imaging and pulmonary function testing. Dr. Mouabbi underlined that novel treatments such as T-DXd represent a turning point in the field and give patients with metastatic breast cancer hitherto unheard-of hope.

You can watch the full conversation between Dr. Gadi and Dr. Mouabbi below to hear more of their experience and analysis of how ADCs are changing HER2-positive breast cancer treatment, therefore offering patients with advanced illness more focused and efficient choices.

🎧 Don’t forget to like, share, and subscribe for more CHM Conversations

#BreastCancer #OncologyPodcast #TDXd #HER2Low #CHMConversations #PrecisionMedicine #CancerResearch

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media